{"id":627966,"date":"2022-11-30T17:44:02","date_gmt":"2022-11-30T17:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=627966"},"modified":"2022-11-30T17:44:02","modified_gmt":"2022-11-30T17:44:02","slug":"hypercalcemia-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-20222032-delveinsight-key-companies-crinetics-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hypercalcemia-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-20222032-delveinsight-key-companies-crinetics-pharmaceuticals_627966.html","title":{"rendered":"Hypercalcemia Market to Grow at a Substantial Growth Rate During the Forecast Period  (2022-2032) &#8211;  DelveInsight | Key Companies &#8211; Crinetics Pharmaceuticals"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1669823328.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hypercalcemia Market to Grow at a Substantial Growth Rate During the Forecast Period  (2022-2032) -  DelveInsight | Key Companies - Crinetics Pharmaceuticals\" src=\"https:\/\/www.abnewswire.com\/uploads\/1669823328.jpeg\" alt=\"Hypercalcemia Market to Grow at a Substantial Growth Rate During the Forecast Period  (2022-2032) -  DelveInsight | Key Companies - Crinetics Pharmaceuticals\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Hypercalcemia market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypercalcemia pipeline products will significantly revolutionize the Hypercalcemia market dynamics.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Hypercalcemia Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Hypercalcemia, historical and forecasted epidemiology as well as the Hypercalcemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Hypercalcemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Hypercalcemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hypercalcemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Hypercalcemia Market Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypercalcemia Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Hypercalcemia is defined as serum calcium concentration two standard deviations above the mean values and is a common metabolic abnormality seen in both inpatient and outpatient settings. Depending on the serum calcium levels, hypercalcemia is categorized either as mild when levels are between 10 to12 mg\/dL, moderate when levels are between 12 to 14 mg\/dL, or severe when levels are more than 14 mg\/dL.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Hypercalcemia Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Hypercalcemia market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period <strong>(2019-2032)<\/strong><\/li>\n<li>According to the study conducted by <strong>Vakiti &amp; Mewawalla<\/strong>, Hypercalcemia of malignancy occurs in approximately <strong>20%<\/strong> of all cancer patients during their clinical course<\/li>\n<li>According to the study conducted by <strong>Gastanaga et al.<\/strong>,<strong> 2&ndash;3%<\/strong> of US cancer patients are affected by HCM each year. While Hypercalcemia is less common in prostatecancer and breast cancer, these patients make up <strong>34%<\/strong> of cancer patients with Hypercalcemia<\/li>\n<li><strong>Key Hypercalcemia Companies:<\/strong> Crinetics Pharmaceuticals, and others<\/li>\n<li><strong>Key Hypercalcemia Therapies:<\/strong> Oral PTH antagonist, and others<\/li>\n<li>The Hypercalcemia epidemiology based on gender analyzed that, no gender differences were found regarding hypercalcemia<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Hypercalcemia Market Report-&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypercalcemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/hypercalcemia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Hypercalcemia Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Hypercalcemia market report covers a descriptive overview and comprehensive insight of the Hypercalcemia Epidemiology and Hypercalcemia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Hypercalcemia market report provides insights on the current and emerging therapies.<\/li>\n<li>Hypercalcemia market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Hypercalcemia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Hypercalcemia market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Hypercalcemia epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypercalcemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Hypercalcemia Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypercalcemia Market &nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Hypercalcemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&ldquo;At present, Amgen, Kyowa Kirin Co., Ltd, and others are actively working towards the development of potential therapy to overcome the unmet medical needs of the currently used therapeutics. &rdquo;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypercalcemia Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypercalcemia Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Hypercalcemia market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Hypercalcemia<\/li>\n<li>Prevalent Cases of Hypercalcemia by severity<\/li>\n<li>Gender-specific Prevalence of Hypercalcemia<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Hypercalcemia<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypercalcemia Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypercalcemia market or expected to get launched during the study period. The analysis covers Hypercalcemia market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Hypercalcemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Hypercalcemia market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypercalcemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Hypercalcemia market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypercalcemia Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Oral PTH antagonist:<\/strong> Crinetics Pharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Hypercalcemia Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Hypercalcemia Companies:<\/strong> Crinetics Pharmaceuticals, and others<\/li>\n<li><strong>Key Hypercalcemia Therapies:<\/strong> Oral PTH antagonist, and others<\/li>\n<li><strong>Hypercalcemia Therapeutic Assessment:<\/strong> Hypercalcemia current marketed and Hypercalcemia emerging therapies<\/li>\n<li><strong>Hypercalcemia Market Dynamics:<\/strong>&nbsp;Hypercalcemia market drivers and Hypercalcemia market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Hypercalcemia Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Hypercalcemia Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\">1. Hypercalcemia Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Hypercalcemia<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Hypercalcemia<\/p>\n<p style=\"text-align: justify;\">4. Hypercalcemia Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Hypercalcemia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Hypercalcemia Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Hypercalcemia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Hypercalcemia&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Hypercalcemia Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Hypercalcemia Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Hypercalcemia Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Hypercalcemia Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Hypercalcemia Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Hypercalcemia Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Hypercalcemia Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Hypercalcemia Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Hypercalcemia Appendix<\/p>\n<p style=\"text-align: justify;\">18. Hypercalcemia Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Hypercalcemia treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypercalcemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Hypercalcemia Medications<\/a> &nbsp;<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hypercalcemia-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-20222032-delveinsight-key-companies-crinetics-pharmaceuticals\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hypercalcemia-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-20222032-delveinsight-key-companies-crinetics-pharmaceuticals\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Hypercalcemia market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypercalcemia pipeline products will significantly revolutionize the Hypercalcemia market dynamics. DelveInsight&rsquo;s &ldquo;Hypercalcemia Market Insights, Epidemiology, and Market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hypercalcemia-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-20222032-delveinsight-key-companies-crinetics-pharmaceuticals_627966.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-627966","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/627966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=627966"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/627966\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=627966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=627966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=627966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}